Despite the proven efficacy of anti-VEGF agents in nAMD treatment, the Comparison of AMD Treatment Trials (CATT) study found that GA was developed in approximately 18% of patients with nAMD treated with anti-VEGF agents for 2 years, and reached 38% at year 5 [7, 8]. This evidence concerns the gene VEGFA and age-related macular degeneration.